CRISPR Therapeutics (CRSP) is a Swiss-based biotechnology company that develops gene-based medicines, most notably using its proprietary CRISPR-Cas9 platform. The company's most advanced product, Casgevy (exagamglogene autotemcel), is a gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed in partnership with Vertex Pharmaceuticals. As of market creation, the company is scheduled to report its fourth quarter and full-year 2025 earnings on February 11, 2026. The Street consensus estimate for GAAP earnings per share (EPS) is -$1.17, and this prediction market resolves 'Yes' if the company reports a GAAP EPS above that figure (i.e., less negative or positive) for the relevant quarter. The resolution source is the company's official earnings release. CRISPR Therapeutics has been a bellwether for the gene-editing industry since its founding in 2013 by Emmanuelle Charpentier, Jennifer Doudna, and others, though both later left the board. The company went public in 2016 at $14 per share, and its stock has been highly volatile, reflecting both the promise of CRISPR technology and the commercial challenges of launching a complex cell therapy. Casgevy received regulatory approval in the UK in November 2023, followed by FDA approval in December 2023 for sickle cell disease and in January 2024 for beta thalassemia. However, commercial uptake has been slow, with a limited number of treatment centers and a complex manufacturing process. In Q3 2025, the company reported revenue of $35.3 million, primarily from Casgevy sales, and a net loss of $187.9 million, with GAAP EPS of -$2.13 (or -$2.11 diluted, depending on the source). The consensus estimate for Q4 has been revised downward over time, reflecting the slow ramp. Investors and traders watch CRISPR Therapeutics' earnings closely because the company is still in the early stages of commercializing a revolutionary but expensive therapy (Casgevy is priced at $2.2 million in the US). The company's cash position, operating expenses, and pipeline progress in oncology and autoimmune diseases are also key factors. The earnings report will provide an update on Casgevy sales, which are expected to grow but may still fall short of aggressive projections. Additionally, the company has faced competition from bluebird bio's Lyfgenia and from other gene-editing approaches, but Casgevy is the only CRISPR-based therapy approved. The market's interest in this specific EPS threshold reflects the importance of meeting or beating consensus, which can influence the stock price and investor sentiment. Beyond the immediate earnings number, this market captures a broader narrative: the transition of a pioneering biotech from research mode to commercial operation. The company's ability to manage costs while scaling up manufacturing and patient access will determine its path to profitability, which analysts project is still several years away. The Q4 2025 results will also set the tone for 2026 guidance, including whether the company can achieve its goal of treating 100+ patients by the end of 2025 (a target that was later revised). For those following the gene-editing sector, this earnings release is a barometer of the commercial viability of CRISPR-based therapies.

Historical Context

CRISPR Therapeutics was founded in 2013, following the groundbreaking discovery of the CRISPR-Cas9 gene-editing system by Emmanuelle Charpentier and Jennifer Doudna in 2012. The company went public in 2016, raising $108 million at $14 per share. In 2015, it entered into a major collaboration with Vertex Pharmaceuticals to develop gene-editing therapies for beta thalassemia and sickle cell disease. This partnership was expanded in 2017, with Vertex paying $175 million upfront and committing to additional milestone payments. The development of CTX001 (later named Casgevy) progressed rapidly, with early clinical data in 2019 showing promising results. In 2021, the companies reported that all treated patients in a phase 1/2 trial were free from vaso-occlusive crises for at least 6 months. The regulatory path for Casgevy was historic: it became the first CRISPR-based therapy to receive approval anywhere in the world when the UK's MHRA approved it in November 2023. The FDA followed in December 2023 for sickle cell disease and in January 2024 for beta thalassemia. However, the launch has been slow. By Q3 2025, only a limited number of patients had been treated, and the company acknowledged that the ramp was below initial expectations. The company's financial history reflects this: in 2023, it reported a net loss of $428 million, and in 2024, the loss widened to $1.2 billion, partly due to one-time charges. The consensus EPS estimates have been consistently negative, and the company has relied on its cash reserves, which stood at $1.5 billion as of September 30, 2025. The broader context includes the competitive landscape. Bluebird bio's Lyfgenia, a lentiviral vector-based therapy, was approved by the FDA in December 2023, but it has had even slower uptake. Additionally, other gene-editing companies like Intellia Therapeutics and Editas Medicine are pursuing similar approaches, but none have a commercial product yet. The success of Casgevy is therefore a bellwether for the entire gene-editing field. The company's earnings reports are closely watched not only by investors but also by clinicians and patients waiting for access to the therapy.